Lung Puncture Guidance: Is Tech Always Best?
"A new study questions whether advanced imaging techniques improve outcomes in peripheral lung biopsies compared to traditional methods."
When it comes to diagnosing lung issues, getting a tissue sample is often crucial. For peripheral lung lesions, doctors frequently use bronchoscopy to obtain these samples. The question is, what's the best way to guide the needle to the right spot?
Traditionally, conventional bronchoscopy with fine needle aspiration has been the go-to method. However, newer technologies like endobronchial ultrasound (EBUS) and electromagnetic navigation (EMN) have emerged, promising greater precision. But do these advanced techniques really improve the odds of a successful biopsy?
A recent study, published in the American Journal of Respiratory and Critical Care Medicine, challenges the assumption that newer is always better. The researchers compared the diagnostic yield of different guidance methods in peripheral lung biopsies.
The Scale and Safety of Lung Biopsy
A study of eligible lung cancer patients recorded 32,814 lung biopsies, averaging 1.7 biopsies per patient. Bronchoscopy and percutaneous approaches accounted for 95% of procedures, and reported complication rates were remarkably similar regardless of biopsy frequency. Separately, researchers analyzed 5,279 bronchoscopies performed from 2016 through 2018 to examine how biopsy techniques performed according to lesion location and pathomorphological type. A 2025 report notes that millions of pulmonary nodules are identified each year through incidental findings or lung cancer screening, creating substantial demand for biopsy to distinguish cancer from benign disease.
Established Methods and Their Tradeoffs
Transbronchial lung biopsy has long been accepted as a conventional method for evaluating interstitial lung diseases, vascular diseases, small-airway diseases, and malignancies. Transbronchial biopsy can be performed without fluoroscopy, although the Merck Manual reports that fluoroscopy may be associated with higher diagnostic yields and a lower incidence of significant pneumothorax. Standard bronchoscopy with fluoroscopy has also been compared with thin bronchoscopy and radial endobronchial ultrasound for sampling lung lesions. Bronchoscopy and lung needle biopsy are minimally invasive, whereas open lung biopsy and thoracoscopy are more invasive, require general anesthesia, and take longer to heal.
From Rigid to Flexible Bronchoscopy
The history of bronchoscopy is described as an evolution of interventional pulmonology marked by historical milestones and changing clinical capabilities. Gustav Killian is regarded as the father of modern bronchoscopy; he examined the trachea and main bronchi of a volunteer using a laryngoscope and later removed airway material. Although lung-biopsy techniques were developed and used through the rigid bronchoscope, flexible bronchoscopy is now standard for this sampling procedure. These developments illustrate the field's movement from early rigid instruments toward more adaptable diagnostic tools.
The Study: Old vs. New
The study analyzed data from 581 bronchoscopies performed on patients with unclear peripheral lung lesions. Researchers looked at how different puncture guidance techniques affected the diagnostic yield – in other words, how often the biopsy successfully provided a diagnosis.
- r-EBUS: This technique uses ultrasound at the tip of the bronchoscope to visualize the lung tissue and guide the needle.
- EMN: This method uses electromagnetic fields to create a 3D map of the lungs, allowing doctors to plan and guide the biopsy.
Navigational Bronchoscopy in Recent Evidence
A recent trial comparing navigational bronchoscopy with transthoracic biopsy found similar diagnostic accuracy but fewer complications with navigational bronchoscopy. Its results suggest that navigational bronchoscopy should be preferred for indeterminate lung nodules that are technically amenable to either approach. A separate 2026 trial is investigating transbronchial lung biopsy with a 1.1-mm cryoprobe versus 2.0-mm forceps. The evidence base also reflects differences in previous biopsy-experience requirements between bronchoscopists at academic centers and radiologists working across community and academic settings.
Risk Remains Procedure- and Patient-Dependent
A systematic review and meta-analysis examined complications of lung biopsy in patients with acute respiratory failure, including acute respiratory distress syndrome. Population-based research has also evaluated complications and associated risk factors after transthoracic needle biopsy of pulmonary lesions. The Merck Manual notes that transbronchial lung biopsy increases complication risk during bronchoscopy, even though it can provide additional diagnostic information and may avoid major surgery. These findings caution against treating biopsy as uniformly low-risk, particularly in medically fragile patients.
Robotic and CT-Guided Sampling
Bronchoscopy and transbronchial lung biopsy are distinct procedures with different uses and indications. A 2025 comparison reported on robotic-assisted bronchoscopy and CT-guided transthoracic biopsy for patients with peripheral lung nodules, focusing on efficiency and diagnostic performance. CT-guided transthoracic biopsy remains the standard biopsy method in the 2026 report, while robotic-assisted biopsy has emerged as a comparable technique. That retrospective study compares patient characteristics, procedure outcomes, and complications between the two approaches.
The Verdict: Stick to the Basics (For Now)
The study's authors concluded that, in their retrospective analysis, electromagnetic and ultrasound-guided navigation systems didn't improve outcomes compared to traditional methods for peripheral lung biopsies.
Accuracy, Safety, and Biomarker Adequacy
A comprehensive systematic review examined current clinical data on the accuracy of bronchoscopy and transthoracic needle biopsy for lung cancer. An expert panel issued recommendations on bronchoscopic biopsies addressing safety and sample adequacy for comprehensive biomarker testing. However, direct comparisons between percutaneous sampling and bronchoscopy, endobronchial ultrasound, or mediastinoscopy remain sparse for diagnostic accuracy. The safest technique and the approach that provides the most adequate material for comprehensive biomarker testing therefore remain uncertain.
Toward Targeted Robotic Bronchoscopy
The bronchoscopes market is expected to grow as respiratory diseases and lung cancer become more prevalent and as minimally invasive diagnostic and therapeutic procedures gain adoption. The same outlook identifies next-generation flexible, robotic-assisted, navigational, and image-guided bronchoscopic systems as development areas. A 2026 review describes robotic-assisted bronchoscopy as poised to play a central role in diagnosis, staging, and potentially localized therapy. Future opportunities also include combining robotic bronchoscopy with molecular diagnostics and liquid biopsy to support comprehensive tumor profiling through minimally invasive procedures.
The Challenge of Interstitial Lung Disease
Interstitial lung disease encompasses more than 200 disorders characterized by lung-parenchymal inflammation and fibrosis. These conditions create significant diagnostic challenges and may require invasive procedures associated with substantial morbidity and mortality risks. Surgical lung biopsy has long been considered the diagnostic gold standard, but its invasiveness, associated morbidity, and limited feasibility in high-risk patients have driven the search for less invasive alternatives. The broader challenge is therefore not simply choosing newer technology, but obtaining an adequate diagnosis while limiting procedural harm.
Technology Gaps in Everyday Care
A 2026 real-world comparative study examines how diagnostic approaches are selected and how diagnostic flow differs in facilities without advanced technologies. Its stated aim is to clarify practice patterns that may help bridge the technological gap in current clinical guidance. Real-world studies presented at ATS 2025 reported that the Van Gogh System's dynamic cell imaging may improve biopsy adequacy, reduce indeterminate samples, and support faster, more confident clinical decisions without disrupting workflow or compromising tissue for downstream testing. A broader review places robotic-assisted bronchoscopy within the evolution of sampling and navigational techniques used for early lung-cancer tissue diagnosis.
In fact, the classic combination of bronchoscopy with fine-needle aspiration under fluoroscopic guidance (a type of X-ray imaging) still appears to be the most effective approach. The researchers suggest sticking with this technique until further prospective studies provide more nuanced insights.
It's important to remember that this study was retrospective, meaning it looked back at data that had already been collected. More research is needed to confirm these findings and explore the potential benefits of newer technologies in specific situations. But for now, the traditional approach remains a solid choice.